Aurinia Pharmaceuticals Inc.(Toronto Stock Exchange : AUPH)
(
)
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | 1.98% | 81.59 | 0.9% | $637.74m | |
| CELG | Celgene Corporation | -0.88% | 135.96 | 1.1% | $563.57m | |
| AMGN | Amgen Inc. | -1.16% | 184.12 | 1.1% | $451.54m | |
| BIIB | Biogen Inc. | -0.63% | 342.42 | 1.2% | $397.97m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.36% | 440.94 | 2.7% | $313.46m | |
| ALNY | Alnylam Pharmaceuticals, Inc | -1.63% | 115.63 | 10.7% | $252.14m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -0.10% | 154.60 | 1.9% | $218.27m | |
| INCY | Incyte Corporation | -0.76% | 114.27 | 2.5% | $205.56m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 0.16% | 140.46 | 1.9% | $180.37m | |
| EXEL | Exelixis, Inc. | -0.25% | 27.46 | 6.5% | $136.95m | |
| ILMN | Illumina, Inc. | -0.21% | 205.18 | 3.5% | $132.63m | |
| BLUE | Bluebird Bio, Inc. | 0.25% | 139.45 | 17.3% | $114.79m | |
| BMRN | BioMarin Pharmaceutical Inc. | -0.55% | 88.13 | 4.4% | $113.12m | |
| SRPT | Sarepta Therapeutics, Inc. | -1.36% | 50.72 | 16.9% | $105.98m | |
| CLVS | Clovis Oncology, Inc. | -2.48% | 76.77 | 16.5% | $102.15m |
Company Profile
Aurinia Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on discovering and developing immunomodulating therapeutics. The company's pipeline includes voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.